Peptides DB
Research-centric peptide and protocol reference hub

ARA 290 record · updated 8h ago

Neuro & moodHealing & recoveryGrade B · human evidenceResearch use only
All 33 studiesJump to the evidenceCompare
What is ARA 290 used for?

ARA 290, also known as a peptide derived from the erythropoietin (EPO) molecule, has garnered attention for its potential therapeutic applications, particularly in the context of nerve regeneration and protection. The peptide is designed to mimic some of the beneficial effects of EPO without eliciting the same erythropoietic activity, which can lead to unwanted side effects such as increased blood viscosity and hypertension.

How it works: Modulates macrophage activity and promotes anti-inflammatory cytokine release

Primarily researched for · Neuro & moodRoute · Subcutaneous injection

Development stage

where ARA 290 sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 164 registered trials. It describes the research record, not a recommendation.

Identity
NameARA 290
Chain length—
Molecular weight1,257.3 Da
FormulaC51H84N16O21
Structure typeNot established
ClassNeuro
Research levelPreclinical
Discovered byAdded before provenance tracking · 2025

Mass and formula from PubChem CID 91810664. No verified residue count for this compound.

Pharmacology
MechanismModulates macrophage activity and promotes anti-inflammatory cytokine release
RouteSubcutaneous injection
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 9, 2026. How this works →
Research stats
Total studies33
Human / animal / cellular17 / 6 / 2
Highest trial phasePreclinical
Years covered2015–2026
Latest study12d ago
Publication history
20152026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

33 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Association between fall location and postoperative clinical outcomes after fragility hip fracture: a multicentre cohort study.
FindingIndoor falls were independently associated with higher risks of mortality (adjusted HR 2.27, 95% CI 1.45-3.54, p<0.001).
Human2026Full text read0.80
From caffeine use motives to sleep disturbance: network and structural equation modeling of caffeine use disorder and depression among caffeine consumers.
FindingCUD had a significant direct effect on sleep problems, p<0.001.
Human2026Full text read0.80
DNA polymerase theta (Polθ): a novel candidate for targeted cancer therapy.
TakeawayPolθ is a promising target for cancer therapy due to its overexpression in tumors, but further clinical validation is needed.
review2026Full text read0.90
Gendered socioeconomic impacts of emerging infectious diseases: Insights from a mixed-methods study in Guinea.
FindingN=906 survey participants aged 18 and over.
Human2026Full text read0.80
Cancer associated fibroblast-T cell crosstalk promotes purinergic synthesis in non-small cell lung cancer (NSCLC).
FindingNot reported in abstract.
In vitro2026Full text read0.80
Real-world evidence on off-label underdosing of direct oral anticoagulants in Asian patients with atrial fibrillation: prescribing patterns, determinants, and outcomes.
Finding20.4% of patients were underdosed.
Human2026Full text read0.80
Mapping the existence and content of heading coaching documents across FIFA members associations.
Finding13 MAs (18.3%) reported having heading coaching material.
review2026Full text read0.70
Limited opportunity for nursing students to perform practical nursing skills during clinical placements: a Scandinavian cross-sectional study.
FindingNot reported in abstract.
Human2023Full text read0.80
Evaluation of dietary curcumin-loaded mesoporous silica nanoparticles on growth, blood biochemistry, gut barrier integrity and enteric gas emissions in weaned piglets.
FindingFinal body weight significantly higher in 30 and 60 mg/kg SL@Cur groups compared to control diet, p<0.05.
Animal2026Full text read0.70
Worldwide diversity of hepatitis A and E viruses in urban wastewater
Finding70% of cities detected Rocahepevirus ratti (rat HEV) genotype C1.
review2026Full text read0.70
Designing for healthy ageing: Lessons learned from engaging pre-frail older adults in the development of digital self-monitoring health technologies
FindingNot reported in abstract.
Human2026Full text read0.80
High-latitude occurrence of Phoebetria palpebrata in the Weddell Sea: new distribution limits and ecological implications
FindingNot reported in abstract.
Human2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching ARA 290 will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much ARA 290 is discussed should be drawn from it.